Abstract

Alvotech will release its quarterly results on August 19, 2026 Post-Mkt, and this preview summarizes consensus expectations for revenue and earnings, last quarter’s performance and mix, and the key regulatory, manufacturing, and funding developments likely to shape the print and forward commentary.

Market Forecast

For the current quarter, the latest forecasts indicate revenue of 111.01 million US dollars, a year-over-year change of -7.88%; the EPS estimate is -0.03, implying a 10.00% year-over-year improvement; forecast EBIT is 10.19 million US dollars, down 60.92% year-over-year. The company has not issued guidance for gross profit margin or net margin for this quarter.

Operationally, the commercial portfolio and licensing activities remain the twin engines of the quarterly P&L, with production having normalized from June and partners expected to resume shipments, while licensing and milestone receipts continue to drive quarter-to-quarter variability. The most promising driver over the next phases is the products business, underpinned by upcoming filings and launch preparation in the United States; last quarter, products generated 51.18 million US dollars, while the overall company revenue contracted 20.26% year-over-year.

Last Quarter Review

Alvotech reported revenue of 105.90 million US dollars (-20.26% year-over-year), a gross profit margin of 56.50%, GAAP net profit attributable to the parent company of 1.03 million US dollars with a net profit margin of 0.97%, and adjusted EPS of -0.09 (-125.71% year-over-year). Despite the revenue contraction tied to manufacturing remediation and regulatory resubmissions earlier in the period, the gross margin held up well due to mix and cost measures. By business line, license and other contributed 54.69 million US dollars (51.62% of total) and products contributed 51.18 million US dollars (48.31% of total), against a -20.26% year-over-year decline for consolidated revenue.

Current Quarter Outlook

Core Commercial and Licensing Portfolio

The company’s quarter-to-quarter performance is highly sensitive to the cadence of product shipments and the timing of license, collaboration, and milestone receipts. With production resuming in June following remediation and inspection activities earlier in the year, the base expectation is for steadier supply to partners and less operational drag on the P&L versus the prior quarter. Even so, consensus anticipates a measured top-line print at 111.01 million US dollars and a modestly improving EPS of -0.03, indicating that licensing and milestone recognition may be more muted this quarter than in periods characterized by larger partner events.

A key read-through for margins in the current update will be the interplay between product mix and any incremental manufacturing efficiencies gained as operations normalized late in the quarter. Historically, quarters with a higher proportion of license and milestone receipts can elevate EBIT but are not always accompanied by proportionate gross margin expansion, while product-heavy quarters can support gross margin consistency but keep earnings levered to volume and price dynamics. Against that backdrop, investors will focus on commentary around gross profit sustainability given last quarter’s 56.50% print and whether efficiencies from the remediation phase are starting to embed in cost of goods sold.

From a cash flow perspective, the balance between working capital needs for expanding production and the inflow from collaborations will matter for the near-term financing trajectory. With funding bolstered recently, the base case is that operational execution rather than balance sheet constraints will be the determinant of near-term revenue and EBIT delivery. Any update on milestone timelines or shipment schedules can quickly shift the expected earnings trajectory this quarter and into the next.

Most Promising Near-Term Growth Avenue

The most visible program-level catalysts tie to U.S. regulatory filings and potential near-term commercial launches, which underpin the “products” business as the primary growth avenue. During June, the company resubmitted U.S. Biologics License Applications for AVT05 (a proposed biosimilar referencing Simponi and Simponi Aria) and AVT06 (a proposed biosimilar referencing Eylea), and announced FDA acceptance of the Biologics License Application for AVT16 (a proposed interchangeable biosimilar referencing Entyvio). These steps, combined with the successful closure of the Reykjavik facility inspection at the end of July, reduce manufacturing uncertainty and reinforce the path toward late-year regulatory decisions and commercialization windows.

While these catalysts are primarily second-half oriented, their preparation influences current-quarter expenses, mix, and guidance commentary. Launch readiness investments, inventory positioning, and partner coordination can weigh on EBIT in the short term, which aligns with the forecasted year-over-year decline in EBIT to 10.19 million US dollars (-60.92% year-over-year). Conversely, greater visibility on launch timing can lift confidence in second-half acceleration, validating the expectation that quarterly results will see a “step-up” as approvals and launches proceed.

The products segment produced 51.18 million US dollars in revenue last quarter, placing it almost on par with license and other. Given the potential for U.S. market entries later in the year, investors will parse this quarter’s remarks for signals on market access, contracting, and the commercial rollout sequence with partners. These details help refine revenue phasing scenarios, particularly for years when loss-of-exclusivity windows can create sharp inflection points in volume and price capture. Although the bulk of the financial impact from these assets is expected beyond the current quarter, the groundwork laid now determines the slope of revenue growth once approvals arrive.

Stock Price Drivers This Quarter

Share performance around the print will likely hinge on two intertwined narratives: confirmation that operations are normalized post-inspection and the degree of confidence management conveys on second-half regulatory and commercial timelines. Evidence of normalized production and steady partner shipments should support the top-line outlook and may reduce concerns that drove last quarter’s revenue shortfall. Any quantification of margin tailwinds from remediation-driven process improvements would be an incremental positive and could mitigate the year-over-year EBIT compression telegraphed by current forecasts.

The funding position is another active variable. The company recently completed a public offering and concurrent private placement that raised an aggregate of 165.00 million US dollars and later secured a 75.00 million US dollars term loan facility. This additional capital reduces balance sheet risk and provides flexibility to execute on launch and scale-up plans; however, investors will watch for updates on the use of proceeds, opex trajectory, and any implications for per-share metrics given potential dilution from equity issuance. Clear articulation of spending priorities and return thresholds can help anchor valuation in the face of near-term earnings volatility.

Regulatory momentum is the third pillar. Updates following the late-July closure of the FDA inspection and the accepted or resubmitted filings will shape sentiment about the pace of approvals. Specific clarity on review timelines, manufacturing readiness, and commercial coordination with partners can shift expectations for the revenue curve in the next two to three quarters. Given consensus expectations for a -7.88% year-over-year revenue change and an EPS improvement to -0.03 this quarter, the stock’s reaction may depend less on the absolute print and more on the strength of management’s second-half roadmap, including how upcoming milestones convert into revenue and earnings.

Analyst Opinions

Bullish views dominate our collected previews for this reporting cycle, with a 100% bullish-to-bearish ratio among named institutional opinions identified. UBS reiterated its Buy rating and 6.00 US dollars price target, characterizing the current period as a “soft quarter” due to production disruptions tied to regulatory resubmissions, yet emphasizing that production resumed in June and forecasting a significant step-up in the second half. The firm lowered its near-term forecasts to 106.00 million US dollars in revenue and 15.00 million US dollars in operating income for the quarter from prior expectations of 146.00 million and 36.00 million, respectively, while stating the risk/reward is skewed to the upside as management keeps late-year approval and launch timelines on track across several assets.

That stance is consistent with the broader theme in published commentary earlier in the year that regulatory setbacks appear reflected in valuation and that the underlying biosimilar franchise has sufficient breadth to sustain growth as manufacturing normalization proceeds. Importantly, the late-July closure of the U.S. facility inspection and the acceptance or resubmission of key U.S. filings in June strengthened the case for a pipeline-to-commercial transition in late 2026, an underpinning for the UBS view that a second-half acceleration is plausible. From an earnings modeling perspective, UBS’s updated figures convey caution for this quarter while maintaining conviction in the near-term trajectory as approvals and launches move closer.

Taken together, the majority institutional lens anticipates a constructive setup into August 19, 2026 Post-Mkt, even if the reported quarter reflects the tail effects of earlier production interruptions and the timing of licensing inflows. The bullish argument rests on three supports: normalization of supply, advancing regulatory dossiers that can unlock late-year and 2027 revenue, and the reinforced liquidity buffer that underwrites execution. For this print, the focus will be on management’s detail around second-half phasing, the durability of gross margin following a 56.50% result last quarter, and any incremental color on milestone timing that could swing EBIT, EPS, or cash generation over the next two reporting periods.